In another clinical trial, named ReACT (A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma), patients with recurrent glioblastomas received either control or rindopepimut. This evidence concerns the gene CSF2 and glioblastoma.